[Anticoagulation as an oncological therapy principle].
The association of cancer with thromboembolic events has been established for more than hundred years. While the thrombophilic diathesis of tumor patients and the neoplastic thrombogenesis have been elucidated pathophysiologically, at least in part, there is growing experimental and clinical evidence that factors of plasmic hemostasis promote tumor growth, angiogenesis, and metastasis. Thus, the rationale for antithrombotic prophylaxis and therapy of tumor patients might not only be based on the prevention of thromboembolic complications but also on the potentially antineoplastic and antimetastatic effects of pharmacological anticoagulation. Encouraging results of clinical studies indicate that prophylactic and therapeutic anticoagulation might improve the survival of selected patients with cancer.
Stockschläder
M
M
Institut für Hämostaseologie und Transfusionsmedizin, Heinrich-Heine-Universität Düsseldorf. stockschlaeder@med.uni-duesseldorf.de
Wenzel
F
F
Zotz
R B
RB
Scharf
R E
RE
D000925:Anticoagulants / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D013923:Thromboembolism / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control
D000925:Anticoagulants